Nautilus Biotechnology, Inc.
Company Stats
- Market Cap
- $180.7M
- as of Sep 30, 2026
- Shares Outstanding
- 127.3M
- Free Float
- 33.1%
Income Statement
- Net Income
- -$59.0M
Cash Flow
- Free Cash Flow
- -$52.0M
- FCF Yield
- -28.8%
- Owner FCF Yield
- -32.5%
Balance Sheet
- Cash & Equivalents
- $12.4M
Returns & Capital
- SBC, 3Y Avg
- $10.6M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | — | -$52.0M | — |
| FY2024 | — | -$61.3M | — |
| FY2023 | — | -$54.2M | — |
| FY2022 | — | -$48.1M | — |
| FY2021 | — | -$41.5M | — |
Annual filing data through FY ended December 31, 2025; shares and float as of October 14, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
TUDRIQEV Prescriptions Start; Nautilus Opens Voyager Access
Stronger demand supports expansion as pricing diverges